Journal of Cancer Survivorship
ISSN 1932-2259 · Springer Science+Business Media · United States · active 2006–2026
Metrics
- Best Scimago quartile (2025)
- Q1
- Cites per paper (2y)
- 3.2
- SJR
- 1.151
- h-index
- 107
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric (how the two differ). Citation rates differ enormously between fields, so compare within a discipline. What the other figures mean: journal quartile, SJR, h-index and article processing charge.
Data as of 8 November 2026 (venue index build).
Scimago Journal Rank 2025
In the Scimago Journal Rank 2025 edition, Journal of Cancer Survivorship is Q1 in 1 of its 2 subject categories and Q2 in the other 1. Its best category quartile is Q1.
| Subject category | Quartile | Rank in category |
|---|---|---|
| Oncology (nursing) | Q1 | #4 of 23 |
| Oncology | Q2 | #120 of 426 |
- Cites per document (2 years, Scopus)
- 4.09
- Documents indexed in 2025 (Scopus)
- 381
The quartile is the one Scimago prints for each category. Rank is the journal's position by SJR among the journals Scimago lists in that category (#1 is the highest); “—” means we hold no rank consistent with that quartile. The document count is what Scopus indexed that year, which can be lower than a journal's full output. Source: SCImago Journal Rank 2025 edition, from Scopus data (scimagojr.com, CC BY-NC).
Journal of Cancer Survivorship is Q1 in 1 of its 2 Scimago subject categories (2025 edition; best category Oncology (nursing): Q1, #4 of 23), with SJR 1.151 (Scimago) and an h-index of 107 (OpenAlex). Listed in Scopus, Web of Science, PubMed.
Is this the right journal for your paper?
The AI Journal Finder ranks the best-matched journals for your paper’s topic — with tier, open access, citation rate and predatory flags. Free to start.
Responding time
- Submission to acceptance
- 100 days (median)Estimated from our library (27 papers)
- Acceptance to publication
- 26 days (median)Estimated from our library (20 papers)
- Submission to publication
- 118 days (median)Estimated from our library (20 papers)
Turnaround figures are indicative, not a guarantee: DOAJ values are self-reported by the journal (average weeks, submission to publication); library estimates are medians of the received/accepted dates printed in papers we hold. Editorial times vary by article type and season — confirm on the journal’s own site.
Indexing & access
- Indexed in
- ScopusWeb of SciencePubMed
- Access status:
- hybrid. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
Scope
Frequently asked
Is Journal of Cancer Survivorship a predatory journal?
Our screening does not flag Journal of Cancer Survivorship. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in Scopus, Web of Science, PubMed, which is a positive signal.
Is Journal of Cancer Survivorship indexed in Scopus or Web of Science?
Per our venue index, Journal of Cancer Survivorship appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is the impact factor of Journal of Cancer Survivorship?
Papers in Journal of Cancer Survivorship are cited about 3.2 times each within two years of publication, and Scimago places it in Q1, with an h-index of 107. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.
What Scimago quartile is Journal of Cancer Survivorship (Q1, Q2, Q3, or Q4)?
In the Scimago Journal Rank 2025 edition, Journal of Cancer Survivorship is Q1 in 1 of its 2 subject categories and Q2 in the other 1. By category: Oncology (nursing): Q1, #4 of 23; Oncology: Q2, #120 of 426. Its best category quartile is Q1. Quartiles split the journals in a subject category into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; Journal of Cancer Survivorship is cited about 3.2 times per paper over two years, with an h-index of 107.
What is the Web of Science (JCR) quartile of Journal of Cancer Survivorship?
The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for Journal of Cancer Survivorship. The open equivalent is its best Scimago quartile, Q1 in Oncology (nursing), derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.
Is Journal of Cancer Survivorship open access?
Our index records its access status as "hybrid". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.
How long does Journal of Cancer Survivorship take to publish a paper?
Submission to acceptance for Journal of Cancer Survivorship takes about 100 days (median) — Estimated from our library (n=27 papers). Treat it as indicative rather than a guarantee: editorial times vary by article type, reviewer availability and season, and a self-reported figure is the journal's own. We do not hold a peer-review acceptance rate for Journal of Cancer Survivorship.
Ready to submit? Tools for your next paper
Similar venues
- Cancer Research and TreatmentQ1 · Korean Cancer Association
- The OncologistQ1 · AlphaMed Press
- Biomolecules and BiomedicineQ2 · Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
- International Journal of Colorectal DiseaseQ2 · Springer Science+Business Media
- Anti-Cancer DrugsQ3 · Lippincott Williams & Wilkins
- Translational Cancer ResearchQ2 · AME Publishing Company
Compare it with its peers: Ranked Oncology journals — ranked by Scimago quartile and cites per paper, predatory venues excluded.